Author Archives: Michael Zilligen from OCH Specialty Marketing - NJ, North America

Oct17

At Face Value

At Face Value Image

The recent 60 Minutes episode on the “eye popping” cost of cancer drugs painted pharmaceutical manufacturers and community oncologists as greedy scoundrels only interested in making huge profits at the expense of desperate cancer patients. Reporter Lesley Stahl keyed in on a common target in the debate over rising healthcare costs—drug price, and a new […]

Posted in Culture, Health & Wellness, medical affairs, Medical Education, Medicine, Patient Communications | Tagged | Comments closed
Mar1

Apples and Oranges?

Biosimilars: The Sophistication of Generics Biologics—therapeutics derived from living cells—remain complex to produce…and reproduce.  Due to the molecular and structural complexity of large (relatively speaking) biologic proteins, a generic biologic equivalent can only be made “similar,” not identical, to the original, hence the industry term “biosimilar”—this is unlike small-molecule drugs, whose chemical structures can be […]

Posted in Efficacy, Technology | Tagged , , , | Comments closed